HK1126216A1 - 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents - Google Patents
2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agentsInfo
- Publication number
- HK1126216A1 HK1126216A1 HK09104901.1A HK09104901A HK1126216A1 HK 1126216 A1 HK1126216 A1 HK 1126216A1 HK 09104901 A HK09104901 A HK 09104901A HK 1126216 A1 HK1126216 A1 HK 1126216A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anticancer agents
- triphenyl
- inhibitors
- interaction
- imidazoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74122305P | 2005-12-01 | 2005-12-01 | |
| US85274706P | 2006-10-19 | 2006-10-19 | |
| PCT/EP2006/068748 WO2007063013A1 (en) | 2005-12-01 | 2006-11-22 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1126216A1 true HK1126216A1 (en) | 2009-08-28 |
Family
ID=37866229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK09104901.1A HK1126216A1 (en) | 2005-12-01 | 2009-06-01 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7851626B2 (ja) |
| EP (3) | EP1960368B1 (ja) |
| JP (1) | JP4870778B2 (ja) |
| KR (2) | KR101109437B1 (ja) |
| CN (1) | CN101316823B (ja) |
| AR (1) | AR057990A1 (ja) |
| AU (1) | AU2006319248B2 (ja) |
| BR (1) | BRPI0619236A2 (ja) |
| CA (1) | CA2630410C (ja) |
| CR (1) | CR9980A (ja) |
| ES (1) | ES2538714T3 (ja) |
| HK (1) | HK1126216A1 (ja) |
| MA (1) | MA31550B1 (ja) |
| NO (1) | NO20082389L (ja) |
| NZ (1) | NZ568285A (ja) |
| RU (1) | RU2442779C2 (ja) |
| TW (1) | TWI326681B (ja) |
| WO (1) | WO2007063013A1 (ja) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009003939A (es) * | 2006-10-19 | 2009-05-11 | Hoffmann La Roche | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. |
| AU2007312390B2 (en) * | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
| CN101784517A (zh) * | 2007-07-06 | 2010-07-21 | 帕拉特克药品公司 | 合成取代的四环素化合物的方法 |
| WO2009047161A1 (en) * | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE |
| WO2010082612A1 (ja) | 2009-01-16 | 2010-07-22 | 第一三共株式会社 | プロリン環構造を有するイミダゾチアゾール誘導体 |
| JP2013503129A (ja) * | 2009-08-26 | 2013-01-31 | ノバルティス アーゲー | テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用 |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| CA2813256A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| EP2651976A1 (en) | 2010-12-16 | 2013-10-23 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
| RU2014128010A (ru) | 2011-12-13 | 2016-02-10 | Бак Инститьют Фо Рисерч Он Эйджин | Способы улучшения средств консервативной терапии |
| EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| TWI654180B (zh) | 2012-06-29 | 2019-03-21 | 美商艾佛艾姆希公司 | 殺真菌之雜環羧醯胺 |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
| WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| CN103012272B (zh) * | 2012-12-21 | 2015-01-28 | 江苏国泰超威新材料有限公司 | 一种咪唑啉化合物的制备方法 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| MX368703B (es) | 2013-02-28 | 2019-10-11 | Amgen Inc | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. |
| MX2015012427A (es) | 2013-03-14 | 2016-01-12 | Amgen Inc | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| RU2016101514A (ru) * | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | ЭКСПРЕССИЯ мРНК ГЕНОВ ДЛЯ ПЕРСОНАЛИЗАЦИИ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ ПАЦИЕНТОВ АНТАГОНИСТОМ MDM2 |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| SG10201913742TA (en) | 2014-04-17 | 2020-03-30 | Univ Michigan Regents | Mdm2 inhibitors and therapeutic methods using the same |
| KR20180035828A (ko) * | 2015-07-10 | 2018-04-06 | 아비나스 인코포레이티드 | 단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| KR20200035944A (ko) | 2017-06-16 | 2020-04-06 | 유니티 바이오테크놀로지, 인크. | 약제학적 용도를 위해 에난티오머적으로 순수한 시스-이미다졸린 화합물을 제조하기 위한 합성 방법 |
| WO2019195851A1 (en) * | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| KR102039696B1 (ko) | 2018-04-23 | 2019-11-04 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 |
| KR102622992B1 (ko) | 2021-03-29 | 2024-01-10 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 및 이의 중간체 제조방법 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
| BR9509024A (pt) * | 1994-09-26 | 1997-09-30 | Shionogi & Co | Derivados de imidazol |
| GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
| WO2003051359A1 (en) | 2001-12-18 | 2003-06-26 | F.Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| CA2468783A1 (en) | 2001-12-18 | 2003-06-26 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
| US6878735B2 (en) * | 2002-05-31 | 2005-04-12 | Board Of Trustees Of Michigan State University | Multi-substituted imidazolines and method of use thereof |
| US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| MXPA05013465A (es) * | 2003-06-17 | 2006-03-09 | Hoffmann La Roche | Cis-imidazolinas como inhibidores de mdm2. |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| RU2319696C2 (ru) * | 2003-06-17 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг | Цис-2, 4, 5-триарил-имидазолины |
| BRPI0511328A (pt) * | 2004-05-18 | 2007-12-04 | Hoffmann La Roche | cis-imidazolinas |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-11-22 EP EP20060819663 patent/EP1960368B1/en active Active
- 2006-11-22 WO PCT/EP2006/068748 patent/WO2007063013A1/en active Application Filing
- 2006-11-22 EP EP09166803A patent/EP2130822A1/en not_active Withdrawn
- 2006-11-22 RU RU2008126383/04A patent/RU2442779C2/ru active
- 2006-11-22 KR KR1020087013226A patent/KR101109437B1/ko active IP Right Grant
- 2006-11-22 EP EP10175570A patent/EP2311814A1/en not_active Withdrawn
- 2006-11-22 NZ NZ568285A patent/NZ568285A/en not_active IP Right Cessation
- 2006-11-22 KR KR1020107024025A patent/KR20100129331A/ko not_active Application Discontinuation
- 2006-11-22 ES ES06819663.3T patent/ES2538714T3/es active Active
- 2006-11-22 JP JP2008542723A patent/JP4870778B2/ja not_active Expired - Fee Related
- 2006-11-22 BR BRPI0619236-0A patent/BRPI0619236A2/pt not_active Application Discontinuation
- 2006-11-22 AU AU2006319248A patent/AU2006319248B2/en not_active Ceased
- 2006-11-22 CA CA2630410A patent/CA2630410C/en not_active Expired - Fee Related
- 2006-11-22 CN CN2006800448100A patent/CN101316823B/zh not_active Expired - Fee Related
- 2006-11-27 US US11/604,558 patent/US7851626B2/en not_active Expired - Fee Related
- 2006-11-29 AR ARP060105272A patent/AR057990A1/es not_active Application Discontinuation
- 2006-11-29 TW TW095144209A patent/TWI326681B/zh not_active IP Right Cessation
-
2008
- 2008-05-16 CR CR9980A patent/CR9980A/es not_active Application Discontinuation
- 2008-05-26 NO NO20082389A patent/NO20082389L/no not_active Application Discontinuation
- 2008-06-02 MA MA30992A patent/MA31550B1/fr unknown
-
2009
- 2009-06-01 HK HK09104901.1A patent/HK1126216A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR057990A1 (es) | 2008-01-09 |
| TW200804297A (en) | 2008-01-16 |
| EP1960368A1 (en) | 2008-08-27 |
| ES2538714T3 (es) | 2015-06-23 |
| NZ568285A (en) | 2011-08-26 |
| NO20082389L (no) | 2008-08-18 |
| JP2009517439A (ja) | 2009-04-30 |
| EP2130822A1 (en) | 2009-12-09 |
| KR20100129331A (ko) | 2010-12-08 |
| CN101316823B (zh) | 2013-05-22 |
| KR20080072894A (ko) | 2008-08-07 |
| US7851626B2 (en) | 2010-12-14 |
| EP2311814A1 (en) | 2011-04-20 |
| WO2007063013A1 (en) | 2007-06-07 |
| US20070129416A1 (en) | 2007-06-07 |
| JP4870778B2 (ja) | 2012-02-08 |
| CN101316823A (zh) | 2008-12-03 |
| AU2006319248A1 (en) | 2007-06-07 |
| AU2006319248B2 (en) | 2012-09-27 |
| EP1960368B1 (en) | 2015-05-06 |
| CA2630410C (en) | 2014-02-25 |
| RU2442779C2 (ru) | 2012-02-20 |
| CR9980A (es) | 2008-06-18 |
| BRPI0619236A2 (pt) | 2011-09-20 |
| MA31550B1 (fr) | 2010-08-02 |
| TWI326681B (en) | 2010-07-01 |
| RU2008126383A (ru) | 2010-01-10 |
| CA2630410A1 (en) | 2007-06-07 |
| KR101109437B1 (ko) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1126216A1 (en) | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents | |
| MX2011012628A (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. | |
| BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
| MY138941A (en) | Aryl-pyridine derivatives | |
| TW200700393A (en) | Novel cis-2,4,5-triaryl-imidazolines | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| GEP20115174B (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| TW200616958A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
| YU65804A (sh) | Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze | |
| TW200738241A (en) | Pyridazine derivatives | |
| MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| MX2010006107A (es) | Derivados de espiroindolinona. | |
| MXPA05010433A (es) | Derivados de pirrolidina y procedimiento para prepararlos. | |
| MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
| CY1115058T1 (el) | Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| TW200616976A (en) | Pyrimidine derivatives | |
| TW200740764A (en) | Pyrazolone derivatives | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| TW200626158A (en) | Naphthaline derivatives | |
| MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| TW200639156A (en) | New compounds | |
| TNSN06220A1 (en) | Benzimidazole derivatives | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| UA96759C2 (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221120 |